Who makes DSP-9632P 27.5 mg?

DSP-9632P 27.5 mg is developed by Sumitomo Pharma Co., Ltd..

What development phase is DSP-9632P 27.5 mg in?

DSP-9632P 27.5 mg is in Phase 1.

Last reviewed 2026-04-20 · How we verify

DSP-9632P 27.5 mg

Sumitomo Pharma Co., Ltd. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	DSP-9632P 27.5 mg
Sponsor	Sumitomo Pharma Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DSP-9632P 27.5 mg CI brief — competitive landscape report
DSP-9632P 27.5 mg updates RSS · CI watch RSS
Sumitomo Pharma Co., Ltd. portfolio CI